Assembly Bill A8075C

2023-2024 Legislative Session

Relates to the availability of opioid reversal agents

download bill text pdf

Sponsored By

Current Bill Status - In Assembly Committee

  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

Bill Amendments

2023-A8075 - Details

See Senate Version of this Bill:
S8991
Current Committee:
Assembly Ways And Means
Law Section:
Mental Hygiene Law
Laws Affected:
Amd §§19.09 & 25.18, Ment Hyg L; amd §3309, Pub Health L

2023-A8075 - Summary

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agent approved by the federal food and drug administration; allows for choice of any formulation and dosage of opioid reversal agent approved by the federal food and drug administration in the purchase, distribution or authorization to prescribe or dispense such products and in any expenditure used for the purchase or distribution of an opioid reversal agent.

2023-A8075 - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   8075
 
                        2023-2024 Regular Sessions
 
                           I N  A S S E M B L Y
 
                            September 27, 2023
                                ___________
 
 Introduced  by M. of A. STECK -- read once and referred to the Committee
   on Alcoholism and Drug Abuse
 
 AN ACT to amend the mental hygiene law and the  public  health  law,  in
   relation to the availability of opioid antagonists
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision (l) of section 19.09 of the mental hygiene law,
 as added by chapter 434 of the laws of  2021,  is  amended  to  read  as
 follows:
   (l)(1)  The  office,  in  consultation  with the department of health,
 shall maintain on its website a  publicly  available  directory  of  all
 distributors  of  opioid  antagonists  to  the public, including but not
 limited to, pharmacies, prevention programs and not-for-profits. As used
 in this subdivision, the following terms shall have the following  mean-
 ings:
   (i)  "Opioid"  means  an  opiate  as  defined  in section thirty-three
 hundred two of the public health law.
   (ii) "Opioid antagonist" means a federal  food  and  drug  administra-
 tion-approved  drug  that,  when administered, negates or neutralizes in
 whole or in part the pharmacological effects of an opioid in  the  body.
 The  opioid antagonist shall be limited to naloxone or other medications
 approved by the department of health for this purpose, PROVIDED,  HOWEV-
 ER,  THAT THE DEPARTMENT OF HEALTH SHALL MAKE  AVAILABLE ANY FORMULATION
 AND DOSAGE OF OPIOID ANTAGONIST THAT ARE APPROVED BY  THE  FEDERAL  FOOD
 AND DRUG ADMINISTRATION.
   (2)  The  directory  required by this subdivision shall include and be
 searchable by the following information:
   (i) addresses of each distributor of opioid antagonists;
   (ii) contact information, such as phone numbers  or  email  addresses,
 for each distributor;
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD11983-01-3
 A. 8075                             2

co-Sponsors

2023-A8075A - Details

See Senate Version of this Bill:
S8991
Current Committee:
Assembly Ways And Means
Law Section:
Mental Hygiene Law
Laws Affected:
Amd §§19.09 & 25.18, Ment Hyg L; amd §3309, Pub Health L

2023-A8075A - Summary

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agent approved by the federal food and drug administration; allows for choice of any formulation and dosage of opioid reversal agent approved by the federal food and drug administration in the purchase, distribution or authorization to prescribe or dispense such products and in any expenditure used for the purchase or distribution of an opioid reversal agent.

2023-A8075A - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  8075--A
 
                        2023-2024 Regular Sessions
 
                           I N  A S S E M B L Y
 
                            September 27, 2023
                                ___________
 
 Introduced  by M. of A. STECK -- read once and referred to the Committee
   on Alcoholism and Drug Abuse -- committee  discharged,  bill  amended,
   ordered reprinted as amended and recommitted to said committee
 
 AN  ACT  to  amend  the mental hygiene law and the public health law, in
   relation to the availability of opioid antagonists

   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision (l) of section 19.09 of the mental hygiene law,
 as  added  by  chapter  434  of  the laws of 2021, is amended to read as
 follows:
   (l)(1) The office, in consultation  with  the  department  of  health,
 shall  maintain  on  its  website  a publicly available directory of all
 distributors of opioid antagonists to  the  public,  including  but  not
 limited to, pharmacies, prevention programs and not-for-profits. As used
 in  this subdivision, the following terms shall have the following mean-
 ings:
   (i) "Opioid" means  an  opiate  as  defined  in  section  thirty-three
 hundred two of the public health law.
   (ii)  "Opioid  antagonist"  means  a federal food and drug administra-
 tion-approved drug that, when administered, negates  or  neutralizes  in
 whole  or  in part the pharmacological effects of an opioid in the body.
 The [opioid antagonist shall be limited to naloxone or other medications
 approved by the department of health for  this  purpose]  DEPARTMENT  OF
 HEALTH  SHALL MAKE AVAILABLE ANY FORMULATION AND DOSAGE OF OPIOID ANTAG-
 ONIST THAT ARE APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION.
   (2) The directory required by this subdivision shall  include  and  be
 searchable by the following information:
   (i) addresses of each distributor of opioid antagonists;
   (ii)  contact  information,  such as phone numbers or email addresses,
 for each distributor;
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD11983-02-3
 A. 8075--A                          2

co-Sponsors

2023-A8075B - Details

See Senate Version of this Bill:
S8991
Current Committee:
Assembly Ways And Means
Law Section:
Mental Hygiene Law
Laws Affected:
Amd §§19.09 & 25.18, Ment Hyg L; amd §3309, Pub Health L

2023-A8075B - Summary

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agent approved by the federal food and drug administration; allows for choice of any formulation and dosage of opioid reversal agent approved by the federal food and drug administration in the purchase, distribution or authorization to prescribe or dispense such products and in any expenditure used for the purchase or distribution of an opioid reversal agent.

2023-A8075B - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  8075--B
 
                        2023-2024 Regular Sessions
 
                           I N  A S S E M B L Y
 
                            September 27, 2023
                                ___________
 
 Introduced  by  M.  of  A.  STECK, FAHY -- read once and referred to the
   Committee on Alcoholism and Drug Abuse -- committee  discharged,  bill
   amended,  ordered reprinted as amended and recommitted to said commit-
   tee -- again reported from said  committee  with  amendments,  ordered
   reprinted as amended and recommitted to said committee

 AN  ACT  to  amend  the mental hygiene law and the public health law, in
   relation to the availability of opioid antagonists
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision (l) of section 19.09 of the mental hygiene law,
 as  added  by  chapter  434  of  the laws of 2021, is amended to read as
 follows:
   (l)(1) The office, in consultation  with  the  department  of  health,
 shall  maintain  on  its  website  a publicly available directory of all
 distributors of opioid antagonists to  the  public,  including  but  not
 limited to, pharmacies, prevention programs and not-for-profits. As used
 in  this subdivision, the following terms shall have the following mean-
 ings:
   (i) "Opioid" means  an  opiate  as  defined  in  section  thirty-three
 hundred two of the public health law.
   (ii)  "Opioid  antagonist"  means  a federal food and drug administra-
 tion-approved drug that, when administered, negates  or  neutralizes  in
 whole  or  in part the pharmacological effects of an opioid in the body.
 The [opioid antagonist shall be limited to naloxone or other medications
 approved by the department of health for  this  purpose]  DEPARTMENT  OF
 HEALTH  SHALL MAKE AVAILABLE ANY FORMULATION AND DOSAGE OF OPIOID ANTAG-
 ONIST THAT ARE APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION.
   (2) The directory required by this subdivision shall  include  and  be
 searchable by the following information:
   (i) addresses of each distributor of opioid antagonists;
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD11983-03-3
 A. 8075--B                          2

co-Sponsors

multi-Sponsors

2023-A8075C (ACTIVE) - Details

See Senate Version of this Bill:
S8991
Current Committee:
Assembly Ways And Means
Law Section:
Mental Hygiene Law
Laws Affected:
Amd §§19.09 & 25.18, Ment Hyg L; amd §3309, Pub Health L

2023-A8075C (ACTIVE) - Summary

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agent approved by the federal food and drug administration; allows for choice of any formulation and dosage of opioid reversal agent approved by the federal food and drug administration in the purchase, distribution or authorization to prescribe or dispense such products and in any expenditure used for the purchase or distribution of an opioid reversal agent.

2023-A8075C (ACTIVE) - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  8075--C
 
                        2023-2024 Regular Sessions
 
                           I N  A S S E M B L Y
 
                            September 27, 2023
                                ___________
 
 Introduced  by  M.  of  A.  STECK, FAHY -- read once and referred to the
   Committee on Alcoholism and Drug Abuse -- committee  discharged,  bill
   amended,  ordered reprinted as amended and recommitted to said commit-
   tee -- again reported from said  committee  with  amendments,  ordered
   reprinted  as amended and recommitted to said committee -- recommitted
   to the Committee on Alcoholism  and  Drug  Abuse  in  accordance  with
   Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered
   reprinted as amended and recommitted to said committee
 
 AN  ACT  to  amend  the mental hygiene law and the public health law, in
   relation to the availability of opioid reversal agents
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision (l) of section 19.09 of the mental hygiene law,
 as  added  by  chapter  434  of  the laws of 2021, is amended to read as
 follows:
   (l)(1) The office, in consultation  with  the  department  of  health,
 shall  maintain  on  its  website  a publicly available directory of all
 distributors of opioid [antagonists]  REVERSAL  AGENTS  to  the  public,
 including  but  not limited to, pharmacies, prevention programs and not-
 for-profits. As used in this subdivision, the following terms shall have
 the following meanings:
   (i) "Opioid" means  an  opiate  as  defined  in  section  thirty-three
 hundred two of the public health law.
   (ii)  "Opioid  [antagonist]  REVERSAL AGENTS" means a federal food and
 drug administration-approved drug that, when  administered,  negates  or
 neutralizes in whole or in part the pharmacological effects of an opioid
 in  the  body.  The  [opioid  antagonist shall be limited to naloxone or
 other medications approved by the department of health for this purpose]
 DEPARTMENT OF HEALTH SHALL MAKE AVAILABLE ANY FORMULATION AND DOSAGE  OF
 OPIOID  REVERSAL  AGENTS  THAT ARE APPROVED BY THE FEDERAL FOOD AND DRUG
 ADMINISTRATION.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD11983-04-4

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.